BioMnoTrpyCD

Provided is raw data expressed as Ct values corresponding to gene expression of human chemokines and their receptors analyzed by using RT² Profiler™ PCR Array Human Chemokines & Receptors (GeneGlobe ID - PAHS-022Z, Qiagen) on a CFX Connect Real-Time PCR System (Biorad, Hercules, CA). Samples: Healthy, mildly and severely inflamed tissue biopsies were collected from all patients and preserved in RNAlater. Tissue samples were obtained from 20 patients of Cronh's disease, grouped by their treatment in 4 groups (untreated, adalimumab, ustekinumab and vedolizumab). Each treatment group has 5 patients associated, with 3 samples from each patient corresponding to the tissue's relative degree of inflammation (Healthy tissue, mildly inflamed tissue, severely inflamed tissue). Clinical and analytical characteristics of patients were recorded at inclusion in the study. Disease clinical activity was determined by Crohn’s disease activity index (CDAI)>150 and presence of clinical symptoms of relapse. Disease endoscopic activity was determined by Simple Endoscopic Score for Crohn Disease (SES-CD). All patients were Caucasian of Mediterranean ethnicity and were classified according to the Montreal classification. All included patients received diaries to record symptoms 1 week before inclusion and sample collection, and signed an informed consent to participate in the study. The study was approved by the Ethics Committee of Hospital General Universitario and performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All patients gave their informed consent prior to their inclusion in the study.

本数据集为原始检测数据，对应采用伯乐（Biorad）CFX Connect实时荧光定量PCR系统（美国加利福尼亚州赫拉克勒斯市），使用凯杰（Qiagen）RT² Profiler™ 人趋化因子及其受体PCR芯片试剂盒（基因全球标识符（GeneGlobe ID）：PAHS-022Z）分析得到的人类趋化因子及其受体基因表达的循环阈值（Ct）值。样本采集：从所有克罗恩病患者中采集健康、轻度炎症及重度炎症的组织活检样本，并保存于RNAlater组织保存液中。本研究共纳入20名克罗恩病患者，按治疗方案分为4组：未治疗组、阿达木单抗（adalimumab）组、乌司奴单抗（ustekinumab）组及维多珠单抗（vedolizumab）组，每组各5名患者。每名患者采集3份样本，对应组织的相对炎症程度：健康组织、轻度炎症组织及重度炎症组织。患者临床特征与研究评估：所有入组患者的临床及分析特征于研究入组时完成记录。疾病临床活动度以克罗恩病活动指数（Crohn’s disease activity index, CDAI）>150及临床复发症状的存在情况进行判定；疾病内镜活动度则采用克罗恩病简易内镜评分（Simple Endoscopic Score for Crohn Disease, SES-CD）进行判定。所有患者均为地中海血统的高加索人种，并依据蒙特利尔分类标准进行疾病分型。研究伦理与流程：所有入组患者均需填写研究日志，记录入组及样本采集前1周的症状情况，并签署知情同意书参与本研究。本研究经综合大学总医院伦理委员会批准，严格遵循1964年《赫尔辛基宣言》及其后续修订版所确立的伦理标准开展。所有患者均在入组研究前签署了知情同意书。